Brief: HLS Therapeutics Announces Health Canada Approval For Vascepa To Reduce Risk Of Cardiovascular Events
31/12/2019 19:22
Dec 31 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES HEALTH CANADA APPROVAL FOR
VASCEPA®
TO REDUCE THE RISK OF CARDIOVASCULAR EVENTS
* HLS THERAPEUTICS INC - COMMERCIAL LAUNCH FOR VASCEPA IN
CANADA
EXPECTED TO TAKE PLACE IN MID-FEBRUARY 2020 TIMEFRAME
Source text for Eikon: ID:nCNWPsCkTa
Further company coverage: HLS.TO
((Reuters.briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease